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DSU-AVR is associated with a lower incidence of paravalvu-
lar leak but with a higher incidence of postoperative atrial
fibrillation. A center that has the ability to perform SAVR,
TAVI (with all its approaches), and SU-AVR is able to offer
the full spectrum of available therapeutic options for
SSAVS and, consequently, can choose the best treatment
for each patient, according to his or her specific clinical
and anatomic features.
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Dr Thierry P. Carrel (Berne, Switzerland). Thank you very
much for the privilege of discussing this paper. The portfolio of
aortic valve replacement has recently been extended by several su-
tureless aortic valve prostheses that have been introduced on the
European market in recent years, but there is no clear-cut indica-
tion for these new types of valves so far. They are all restricted
to the treatment of a stenotic aortic valve, and the main advantage
claimed by the manufacturers is the reduction of the aortic cross-
clamp time. Some recent studies on very limited patient popula-
tions seem to confirm these findings so far.
In isolated aortic valve replacement, the crossclamp time is the
major determinant of cardiopulmonary bypass duration, but less
evidence exists of the role of the crossclamp time in affecting
the outcome neither in the general cardiac population nor in the
specific population treated for isolated aortic valve stenosis. No
study so far has addressed the selection of patients at particular
benefit for a significant reduction in crossclamp time for aortic
valve stenosis.
So the current study, although it addresses only certain interest-
ing aspects of aortic valve replacement, is a timely, nice studygery c November 2012
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procedure is the optimal one to treat aortic valve stenosis on an in-
dividual case-by-case appreciation. And the most interesting mes-
sage is that the incidence and severity of paravalvular leakage was
higher in the TAVI group than in the surgical group, although 15%
of paravalvular leakage is still not acceptable for a surgical
procedure!
So I have three questions for the authors. Could you give a short
comment on the learning curve to feel comfortable when using
a sutureless valve, and which surgical access do you consider to
be the best one for a sutureless valve implantation? Frankly speak-
ing, I found 44 minutes still a long crossclamp time for isolated su-
tureless valve implantation, and I ask this question because we
have found sutureless valve implantation through a less-invasive
approach to be somewhat cumbersome as long as the introducing
devices for these valves are not flexible enough to permit easy de-
ployment under perfect visualization.
Second question: A large majority of TAVI procedures are per-
formed through a transfemoral approach worldwide. Why did you
select only the transapical approach as a comparison group when
the sutureless valves may well address also those patients sched-
uled for a transfemoral approach?
And finally, I would like to question the size of the aortic annu-
lus. Because TAVI was available for sizes 23 and 26, but sutureless
valves only for sizes 21 and 23, do you think that the absence of
difference in the pressure gradients seen in the postoperative
echo between these 2 valves is a result of the fact that large sizes
were implanted only in TAVI and smaller sizes in sutureless
valves? I would expect sutureless performing much better than
TAVI, because the valve can be excised during a sutureless valve
procedure.
Thank you very much again.
Dr D’Onofrio. Dr Carrel, thank you for your questions. The
learning curve of sutureless aortic valve implantation is less de-
manding than the learning curve for TAVI, especially for cardiac
surgeons, who are more used to a surgical approach than to a cath-
eter-based approach.
Crossclamp time in this series for isolated valve replacement
was 44 minutes, but in the literature it has been shown that the
crossclamp time can be as low as 18 minutes. I believe that this dif-
ference is mainly a result of the learning curve and the fact that
these were the very first cases that we have done in Italy. Regard-
less, we observe that, as experience increases, the crossclamp
times reduce progressively. So I am pretty sure that, in future stud-
ies, we will show shorter crossclamp times.
The great majority of centers that participate to the Italian
Transapical registry, called ITA, are based on a transfemoral-first
approach. Our registry includes only transapical procedures, and
for this study we didn’t have the possibility to retrieve transfemoral
data as well. However, because transfemoral procedures are per-
formed mainly by interventional cardiologists, in this study we ob-
served cardiac surgeons performing both transcatheter and
surgical procedures, and this is quite interesting.
There were no differences in terms of gradients between trans-
apical and sutureless valves. It is a very small series, so I don’t
think we can draw any final conclusion from this study. Actually,
I don’t think that label size has a big importance regarding trans-
valvular gradients.The Journal of Thoracic and CarI hope I answered all your questions.
Dr Joseph F. Sabik (Cleveland, Ohio). I have a question about
the technical aspects of deploying the sutureless valves. How ag-
gressive do you debride the calcium in the aortic annulus? Do
you want some calcium left behind to hold the valve in place—
let’s just say like a transcatheter valve—or do you want to debride
it aggressively like we would do in an open procedure?
DrD’Onofrio.We take the calciumaway fromthe annulus, but it
is not important to take away everything as for conventional valves.
We just want to have a homogenous, round-shaped annulus even
with some calcium, so that the valve can be implanted smoothly.
Dr Sabik. Does debridement influence whether you have any
leakage around the valve?
Dr D’Onofrio. Sorry?
Dr Sabik. How aggressively you debride, does that influence
the leakage around the valve, if there is any, any paravalvular aortic
insufficiency?
Dr D’Onofrio.Yes, we observed a small incidence of paravalv-
ular leak in sutureless valves. The most important thing is to have
a round-shaped homogeneous debridement without bulky pieces
of calcium in the annulus before sutureless valve implantation.
We did not observe a relationship between the extension of annular
decalcification and paravalvular leak.
Dr Khaled D. Algarni (Toronto, Ontario, Canada). You have
done a very good job trying to match these 2 groups; however,
frailty is an important confounder that you perhaps haven’t ac-
counted for. Do you think that in the TAVI group there were
more patients who were frail than in the sutureless valve group?
And that might explain the higher mortality in the TAVI group?
Dr D’Onofrio. Of course, frailty is important, but we didn’t
collect specific data about this aspect, so we were not able to in-
clude any frailty index as a variable into the statistical analysis.
The logistic EuroSCORE of the matched TAVI population was
lower than the logistic EuroSCORE of the entire TAVI cohort.
This is because propensity matching selected patients with a low
logistic EuroSCORE. And the indication of these patients for
TAVI was based mainly on frailty, rather than on EuroSCORE,
but unfortunately we don’t have a numeric value for that.
Dr Mustafa Cikirikcioglu (Geneva, Switzerland). First of all,
I congratulate the authors for a timely report on sutureless aortic
valves. My question is concerning the paravalvular leak rate.
You announced 15% of paravalvular leak for the Perceval
group. Do you think this is an acceptable percentage for a surgi-
cal aortic valve replacement group? And my second question:
Why did you not choose a third group of patients that would
include only surgically and standard aortic valve replacement?
Thank you.
Dr D’Onofrio. I want to answer your second question first. We
are now designing a new study considering all 3 groups—trans-
catheter, sutureless, and surgical aortic valve. I hope it will be
done in the very near future.
Dr Cikirikcioglu. And, in your opinion, is it acceptable?
Dr D’Onofrio.We have to consider that this is just a very pre-
liminary and a very initial experience, so there is a learning curve.
The leaks were always mild, and I think that in the future the inci-
dence of paravalvular leak will go down for sure. It is like trans-
catheter valves; we are now learning how to make sizing, how to
make deployment. We are learning a lot of things, and I thinkdiovascular Surgery c Volume 144, Number 5 1017
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learning curve, I believe that results will improve.
Dr Keith B. Allen (Kansas City, Mo). I want to follow up on
that last question. We know from recent PARTNER data that
even mild paravalvular leak has a negative impact on mortality.
You may not have known that when you were doing this study
but, moving forward, is that knowledge going to change how
you will use the sutureless valve? Because you have the patient
open and on bypass, and putting in some type of a sewn-in valve
may only add 10 or 15 minutes to the operation without the com-
plication of paravalvular leaks?
Dr D’Onofrio. Yes, I totally agree with you. Paravalvular leak
is a very important determinant of early and late results in aortic
valve patients, and I think that with sutureless valves we just
have to identify who are the right patients who need this procedure.
And for this reason, I think we have to find a compromise and to
accept a low rate of paravalvular leak. However, as I said before,1018 The Journal of Thoracic and Cardiovascular Surwith the learning curve and with experience I think that our results
will improve for sure.
Dr Behzad Soleimani (Hershey, Pa). Thank you for your clear
presentation. I have a question again on the paravalvular leak in
the sutureless group. How many of the paravalvular leaks were
detected at the end of the procedure with on-table transesopha-
geal echocardiogram (TEE)? And second, if you had more than
mild AI, what would have been your strategy in the operating
room?
Dr D’Onofrio. Four of these minor leaks were found at predis-
charge examination, and only 2 were found on the intraoperative
TEE. We decided not to touch these minor leaks, because the pro-
cedure was really complex and it would have been worse to clamp
the aorta again to fix just a minor leak. In case a moderate leak is
found, the behavior is similar to conventional aortic valve replace-
ment. If we find a moderate leak, we go on pump again, we clamp
the aorta, and we fix it.gery c November 2012
